Our Pipeline

We’re focused on the innovative application of science and medicine

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect our ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurologic and respiratory disorders.

Candidate Indication/Target Phase
003 APL-130277 OFF episodes associated with Parkinson’s disease Registration (U.S.)
004 Dasotraline Attention deficit hyperactivity disorder (ADHD), adult and pediatric Registration (U.S.)
005 Eslicarbazepine acetate Partial-onset seizures (monotherapy) Registration (Canada)
006 Eslicarbazepine acetate Partial-onset seizures, pediatric (monotherapy/adjunctive therapy) Registration (Canada)
007 Dasotraline Binge eating disorder (BED), adult Phase 3
008 SB623 Chronic stroke Phase 2
009 SEP-363856 Schizophrenia Phase 2
010 SEP-363856 Parkinson’s disease psychosis Phase 2
011 SEP-4199 Bipolar depression Phase 2
012 DSP-2230 Neuropathic pain Phase 1
013 DSP-3905 Neuropathic pain Phase 1
014 DSP-6745 Parkinson's disease psychosis Phase 1
015 SEP-378608 Bipolar disorder Phase 1